Tracing the recent updates on vaccination approaches and significant adjuvants being developed against HIV

Shiza Malik, Khalid Muhammad, Sanaa Masood Aslam, Yasir Waheed

Research output: Contribution to journalReview articlepeer-review


Introduction: Human Immunodeficiency Virus type 1 (HIV1); the causative agent of Acquired Immunodeficiency Syndrome (AIDS), has been a major target of the scientific community to develop an anti-viral therapy. Some successful discoveries have been made during the last two decades in the form of availability of antiviral therapy in endemic regions. Nevertheless, a total cure and safety vaccine has not yet been designed to eradicate HIV from the world. Areas covered: The purpose of this comprehensive study is to compile recent data regarding therapeutic interventions against HIV and to determine future research needs in this field. A systematic research strategy has been used to gather data from recent, most advanced published electronic sources. Literature based results show that experiments at the invitro level and animal models are continuously in research annals and are providing hope for human trials. Expert Opinion: There is still a gap and more work is needed in the direction of modern drug and vaccination designs. Moreover coordination is necessary among researchers, educationists, public health workers, and the general community to communicate and coordinate the repercussions associated with the deadly disease. It is important for taking timely measures regarding mitigation and adaptation with HIV in future.

Original languageEnglish
Pages (from-to)431-446
Number of pages16
JournalExpert Review of Anti-Infective Therapy
Issue number4
Publication statusPublished - 2023


  • HIV1
  • clinical trials
  • drug adjuvants
  • iImmune responses
  • vaccines
  • viral biology

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology


Dive into the research topics of 'Tracing the recent updates on vaccination approaches and significant adjuvants being developed against HIV'. Together they form a unique fingerprint.

Cite this